NCT04710628: PECATI

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Completed Phase 2 Last updated 19 February 2026

What this trial tests

Phase 2 trial testing Pembrolizumab in Metastatic Thymic Carcinoma in 43 participants. Completed in 16 February 2026.

Timeline

21 September 2021

Primary endpoint
1 July 2024

16 February 2026

Quick facts

Lead sponsor	MedSIR
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	21 September 2021
Primary completion	1 July 2024
Estimated completion	16 February 2026
Sites	13 locations across France, Spain, Italy

Drugs / interventions tested

• Pembrolizumab (pembrolizumab) — full drug profile →
• Lenvatinib 10 mg — full drug profile →

Conditions studied

• Metastatic Thymic Carcinoma — all drugs for Metastatic Thymic Carcinoma →
• Thymoma Type B3 — all drugs for Thymoma Type B3 →

Sponsor

MedSIR — full company profile →

Who can join

18 and older, any sex, with Metastatic Thymic Carcinoma or Thymoma Type B3. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma patients who have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 status.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
   Ao YQ, Gao J, Wang S, Jiang JH, et al · · 2023 · cited 32× · PMID 37055838 · DOI 10.1186/s12943-023-01772-4
2. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
   Girard N, Ponce Aix S, Cedres S, Berghmans T, et al · · 2023 · cited 30× · PMID 37285717 · DOI 10.1016/j.esmoop.2023.101576
3. An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances.
   Tateo V, Manuzzi L, Parisi C, De Giglio A, et al · · 2021 · cited 16× · PMID 33915954 · DOI 10.3390/ph14040316
4. Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment.
   Masaoutis C, Palamaris K, Kokkali S, Levidou G, et al · · 2022 · cited 15× · PMID 35887212 · DOI 10.3390/ijms23147864
5. Current Treatment Approaches for Thymic Epithelial Tumors.
   Tartarone A, Lerose R, Lettini AR, Tartarone M. · · 2023 · cited 14× · PMID 37240815 · DOI 10.3390/life13051170
6. Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions.
   Rajan A, Sivapiromrat AK, McAdams MJ. · · 2024 · cited 12× · PMID 38611047 · DOI 10.3390/cancers16071369
7. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
   Remon J, Bernabé R, Diz P, Felip E, et al · · 2022 · cited 12× · PMID 35122634 · DOI 10.1007/s12094-022-02788-w
8. Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours.
   Dumoulin DW, Bironzo P, Passiglia F, Scagliotti GV, et al · · 2023 · cited 9× · PMID 36754434 · DOI 10.1183/16000617.0174-2022